Cargando…
Adopting Consensus Terms for Testing in Precision Medicine
Despite the well-understood benefits of biomarker and genetic testing in precision medicine, uptake remains low, particularly for patients with low socioeconomic status and minority ethnic backgrounds. Patients report having limited familiarity with testing terminology and may not be able to accurat...
Autores principales: | Martin, Nikki A., Tepper, Joel E., Giri, Veda N., Stinchcombe, Thomas E., Cheng, Heather H., Javle, Milind M., Konnick, Eric Q. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509918/ https://www.ncbi.nlm.nih.gov/pubmed/34651094 http://dx.doi.org/10.1200/PO.21.00027 |
Ejemplares similares
-
The regulatory landscape of precision oncology laboratory medicine in the United States – Perspective on the past 5 years and considerations for future regulation
por: Konnick, Eric Q.
Publicado: (2020) -
Consensus Statements on Precision Oncology in the China Greater Bay Area
por: Lam, Tai-Chung, et al.
Publicado: (2023) -
Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders
por: Beversdorf, David Q.
Publicado: (2016) -
The economic case for precision medicine
por: Gavan, Sean P., et al.
Publicado: (2018) -
Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer
por: Quintanar, T., et al.
Publicado: (2020)